Author: Di Micco, Simone; Musella, Simona; Sala, Marina; Scala, Maria C.; Andrei, Graciela; Snoeck, Robert; Bifulco, Giuseppe; Campiglia, Pietro; Fasano, Alessio
                    Title: Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation  Cord-id: wgkhtn9s  Document date: 2021_8_30
                    ID: wgkhtn9s
                    
                    Snippet: A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified as the pathogen responsible for the outbreak of a severe, rapidly developing pneumonia (Coronavirus disease 2019, COVID-19). The virus enzyme, called 3CLpro or main protease (M(pro)), is essential for viral replication, making it a most promising target for antiviral drug development. Recently, we adopted the drug repurposing as appropriate strategy to give fast response to global COVID-19 epid
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified as the pathogen responsible for the outbreak of a severe, rapidly developing pneumonia (Coronavirus disease 2019, COVID-19). The virus enzyme, called 3CLpro or main protease (M(pro)), is essential for viral replication, making it a most promising target for antiviral drug development. Recently, we adopted the drug repurposing as appropriate strategy to give fast response to global COVID-19 epidemic, by demonstrating that the zonulin octapeptide inhibitor AT1001 (Larazotide acetate) binds M(pro) catalytic domain. Thus, in the present study we tried to investigate the antiviral activity of AT1001, along with five derivatives, by cell-based assays. Our results provide with the identification of AT1001 peptide molecular framework for lead optimization step to develop new generations of antiviral agents of SARS-CoV-2 with an improved biological activity, expanding the chance for success in clinical trials.
 
  Search related documents: 
                                Co phrase  search for related documents- acceptor donor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
  - access date and acute respiratory syndrome: 1
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date